Cancer immunoediting: Antigens, mechanisms, and implications to cancer immunotherapy

Matthew D. Vesely, Robert D. Schreiber

Research output: Contribution to journalArticlepeer-review

200 Scopus citations

Abstract

Accumulated data from animal models and human cancer patients strongly support the concept that the immune system can identify and control nascent tumor cells in a process called cancer immunosurveillance. In addition, the immune system can also promote tumor progression through chronic inflammation, immunoselection of poorly immunogenic variants, and suppressing antitumor immunity. Together, the dual host-protective and tumor-promoting actions of immunity are referred to as cancer immunoediting. The current framework of cancer immunoediting is a dynamic process comprised of three distinct phases: elimination, equilibrium, and escape. Recently, we demonstrated that immunoselection by CD8+ T cells of tumor variants lacking strong tumor-specific antigens represents one mechanism by which cancer cells escape tumor immunity and points toward the future of personalized cancer therapy.

Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalAnnals of the New York Academy of Sciences
Volume1284
Issue number1
DOIs
StatePublished - May 2013

Keywords

  • Cancer genome
  • Cancer immunoediting
  • Immunosurveillance
  • Immunotherapy
  • Tumor antigens
  • Tumor escape

Fingerprint

Dive into the research topics of 'Cancer immunoediting: Antigens, mechanisms, and implications to cancer immunotherapy'. Together they form a unique fingerprint.

Cite this